Phase I/II trial of ISIS3521, an antisense inhibitor of PKC alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Yuen, A., Halsey, J., Lum, B., Fisher, G., Advani, R., Geary, R., Kwoh, T. J., Holmlund, J. T., Dorr, A., Sikic, B. I. AMER ASSOC CANCER RESEARCH. 2000: 4572S

View details for Web of Science ID 000165409000487